Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells.
Ibáñez-Navarro M, Fernández A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero MÁ, Leivas A, Caracuel BR, Rodríguez-Antolín C, Ortiz A, Navarro-Zapata A, Mestre-Durán C, Izquierdo M, Balaguer-Pérez M, Ferreras C, Martínez-López J, Valés-Gómez M, Pérez-Martínez A, Fernández L. Ibáñez-Navarro M, et al. Among authors: escudero a. Front Immunol. 2023 Oct 18;14:1187665. doi: 10.3389/fimmu.2023.1187665. eCollection 2023. Front Immunol. 2023. PMID: 37928520 Free PMC article.
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A. Fernández L, et al. Among authors: escudero a. Clin Cancer Res. 2017 Oct 1;23(19):5824-5835. doi: 10.1158/1078-0432.CCR-17-0075. Epub 2017 Jun 28. Clin Cancer Res. 2017. PMID: 28659311
Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M, Bueno D, González-Navarro P, Brito A, Fernández L, Escudero A, Valentín J, Mestre-Durán C, Arranz-Álvarez M, Pérez de Diego R, Mendiola M, Pozo-Kreilinger JJ, Pérez-Martínez A. Vela M, et al. Among authors: escudero a. Front Immunol. 2019 Aug 2;10:1814. doi: 10.3389/fimmu.2019.01814. eCollection 2019. Front Immunol. 2019. PMID: 31428099 Free PMC article.
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L, Fernández A, Mirones I, Escudero A, Cardoso L, Vela M, Lanzarot D, de Paz R, Leivas A, Gallardo M, Marcos A, Romero AB, Martínez-López J, Pérez-Martínez A. Fernández L, et al. Among authors: escudero a. Front Immunol. 2019 Oct 10;10:2361. doi: 10.3389/fimmu.2019.02361. eCollection 2019. Front Immunol. 2019. PMID: 31649672 Free PMC article.
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Fernández A, Pérez-Martínez A, Escudero A, Mirones I, González B, de Paz R, Matamala N, Clares L, Navarro A, Galán V, Martínez-Romera I, Martínez-López J, Leivas A, Valés-Gómez M, Ferreras C, Fernández L. Fernández A, et al. Among authors: escudero a. Leuk Lymphoma. 2022 Aug;63(8):1970-1974. doi: 10.1080/10428194.2022.2057490. Epub 2022 Apr 3. Leuk Lymphoma. 2022. PMID: 35369829 No abstract available.
Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Mestre-Durán C, Martín-Cortázar C, García-Solís B, Pernas A, Pertíñez L, Galán V, Sisinni L, Clares-Villa L, Navarro-Zapata A, Al-Akioui K, Escudero A, Ferreras C, Pérez-Martínez A. Mestre-Durán C, et al. Among authors: escudero a. Front Immunol. 2023 Jan 5;13:1045316. doi: 10.3389/fimmu.2022.1045316. eCollection 2022. Front Immunol. 2023. PMID: 36685552 Free PMC article.
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A. Vela M, et al. Among authors: escudero a. Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23. Cancer Lett. 2018. PMID: 29477379 Clinical Trial.
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM, Escudero A, Mestre C, Fuster Soler JL, Martínez AP, Vagace Valero JM, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, De Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Gómez García LM, et al. Among authors: escudero a. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):328-337.e1. doi: 10.1016/j.clml.2021.01.013. Epub 2021 Jan 25. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33610500 Clinical Trial.
How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodríguez R, Torres JM, Díaz-Almirón M, López-Collazo E, Martinez-Lopez J, Pérez-Martínez A. Fernández L, et al. Among authors: escudero a. Transfusion. 2018 Jun;58(6):1340-1347. doi: 10.1111/trf.14573. Epub 2018 Mar 14. Transfusion. 2018. PMID: 29542132
478 results